Syndicate content The Healthcare Sales & Marketing Network
Healthcare Sales & Marketing Network NewsFeed
Updated: 31 min 40 sec ago

Ken Keller Named President, US Commercial, Daiichi Sankyo, Inc.

Fri, 04/18/2014 - 14:58
PARSIPPANY, N.J., April 18, 2014 -- (Healthcare Sales & Marketing Network) -- Daiichi Sankyo, Inc. announced today that Ken Keller will join the company as President of its Commercial operations in the United States starting May 1, 2014. In his role, Mr....
Biopharmaceuticals, Personnel
Daiichi Sankyo

Sanovas Fortifies Patent Estate for its "Smart Catheter" Portfolio: Resector Balloon System Patent Strengthens Vas Zeppelin(TM) Platform

Fri, 04/18/2014 - 12:40
SAUSALITO, Calif., April 18, 2014 -- (Healthcare Sales & Marketing Network) -- Sanovas Inc. (, a Life Sciences Accelerator developing and commercializing next-generation micro-invasive diagnostics, devices and drug delivery technologies, a...
Sanovas, Resector Balloon, Vas Zeppelin

Teva Settles Patent Litigation with Pfizer on Celebrex(R)

Thu, 04/17/2014 - 20:24
JERUSALEM--(Healthcare Sales & Marketing Network)--Teva Pharmaceutical Industries Ltd. (TEVA) announced today that its subsidiary Teva Pharmaceuticals USA, Inc. has entered into a settlement with Pfizer related to Teva’s generic version of Celebrex® (c...
Biopharmaceuticals, Generics, Litigation
Teva Pharmaceutical, Pfizer, Celebrex, celecoxib

ZipLine(R) Medical Receives CE Mark and Regulatory Approvals in Japan and South Korea for Zip(R) Surgical Skin Closure, Begins International Distribution

Thu, 04/17/2014 - 15:25
Zip® Non-Invasive Surgical Skin Closure Device is Faster than Sutures, Can Produce Superior Cosmesis Compared to Staples and Reduce the Risk of Surgical Site Infection CAMPBELL, Calif.--(Healthcare Sales & Marketing Network)--ZipLine Medical announc...
Devices, Distribution, Surgery
ZipLine Medical, Cosmotec Co, Zip surgical, skin-closure devices

Gamma Medica Creates Strategic Advisory Board Chaired by Veteran Health Technology Executive Robert Cascella

Thu, 04/17/2014 - 15:18
SALEM, N.H.--(Healthcare Sales & Marketing Network)--Gamma Medica, developer of advanced digital molecular imaging technologies for the detection of breast cancer, announced today that it has formed a strategic advisory board comprised of distinguished cli...
Devices, Personnel
Gamma Medica , LumaGEM, Molecular Breast Imaging

Neurosurgery journal published study reinforces value of high-field iMRI

Thu, 04/17/2014 - 15:10
VISIUS intraoperative MRI significantly enhances amount of complete resection in brain tumors and leads to better patient outcomes MINNEAPOLIS, April 17, 2014 -- (Healthcare Sales & Marketing Network) - IMRIS Inc. (NASDAQ: IMRS; TSX: IM) ("IMRIS&q...
Devices, Neurosurgery, Radiology
IMRIS, high-field intraoperative MRI, IMRIS VISIUS, iMRI

Uroplasty Names Daniel P. Merz As Vice President Of Healthcare Affairs

Thu, 04/17/2014 - 15:01
MINNEAPOLIS, April 17, 2014 -- (Healthcare Sales & Marketing Network) -- Uroplasty, Inc. (UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced th...
Devices, Urology, Personnel
Uroplasty, Urgent PC, Neuromodulation

Nora Therapeutics Announces $18 Million Series B Financing

Thu, 04/17/2014 - 14:18
To support continued development of NT100, including addition of Ph2 RESPONSE trial in recurrent pregnancy loss indication PALO ALTO, Calif., April 17, 2014 -- (Healthcare Sales & Marketing Network) -- Nora Therapeutics, a biotechnology company focused...
Biopharmaceuticals, Venture Capital
Nora Therapeutics, NT100, THRIVE-IVF, IVF

Heart Metabolics Limited Launched in Ireland with $20 Million Series A Financing

Thu, 04/17/2014 - 14:13
DUBLIN, April 17, 2014 -- (Healthcare Sales & Marketing Network) -- Heart Metabolics Limited, a new Irish biotechnology company focused on development of drugs for cardio-metabolic diseases, has announced the completion of a $20 million Series A financing...
Biopharmaceuticals, Cardiology, Venture Capital
Heart Metabolics, perhexiline, hypertrophic cardiomyopathy

ForSight VISION5 Completes $15MM Series C Funding Round; Company Finishes Enrolling Phase 2 Clinical Study

Wed, 04/16/2014 - 21:04
MENLO PARK, Calif., April 16, 2014 -- (Healthcare Sales & Marketing Network) -- ForSight VISION5 is pleased to announce it has recently closed its Series C round of funding and has also completed enrollment in its Phase 2 Clinical Study for the HeliosTM o...
Biopharmaceuticals, Ophthalmology, Venture Capital
ForSight VISION5, Helios insert, drug delivery

23andMe Appoints Dr. Jill Hagenkord Chief Medical Officer

Wed, 04/16/2014 - 20:41
23andMe Taps Top Talent to Help Incorporate Genetics Into Medical Practice MOUNTAIN VIEW, Calif.--(Healthcare Sales & Marketing Network)--23andMe, the leading personal genetics company, today announced the appointment of Dr. Jill Hagenkord as chief medi...
Diagnostics, Personalized Medicine, Personnel
23andMe, personal genetics, personalize health

Vasomedical Announces Cooperative Agreement with PSK for International Marketing of ECP Systems

Wed, 04/16/2014 - 13:39
WESTBURY, N.Y., April 16, 2014 -- (Healthcare Sales & Marketing Network) -- Vasomedical, Inc. ("Vasomedical") (OTC BB: VASO), a diversified medical technology company specializing in the design, manufacture and sale of medical devices, including...
Devices, Cardiology, Distribution
Vasomedical, VSK Medical Limited, EECP Therapy

Dyax Corp. Announces Appointment of Todd Bazemore as Chief Commercial Officer

Wed, 04/16/2014 - 13:30
BURLINGTON, Mass.--(Healthcare Sales & Marketing Network)--Dyax Corp. (DYAX) announced today the appointment of Todd Bazemore as Executive Vice President and Chief Commercial Officer. Mr. Bazemore will be responsible for leading Dyax’s commercial organizat...
Biopharmaceuticals, Personnel
Dyax Corp, KALBITOR, ecallantide, hereditary angioedema

Cardiac Dimensions(R) Completes $20 Million Equity Financing

Wed, 04/16/2014 - 13:26
Funding Will Enable Initiation of Blinded, Randomized Clinical Trial and Expanded Commercialization of CARILLON® Mitral Contour System® KIRKLAND, Wash., April 16, 2014 -- (Healthcare Sales & Marketing Network) -- Cardiac Dimensions®, Inc. t...
Devices, Interventional Cardiology, Venture Capital
Cardiac Dimensions, Mitral Contour, mitral regurgitation, mitral valve

Astellas US Promotes Jeffrey Bloss to SVP of Medical Affairs for the Americas

Wed, 04/16/2014 - 13:19
Bloss to serve on Astellas US Management Committee NORTHBROOK, Ill., April 16, 2014 -- (Healthcare Sales & Marketing Network) -- Astellas US LLC, a subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo:4503), announced Jeffrey D. Bloss, M.D., has been ...
Biopharmaceuticals, Personnel
Astellas US, Astellas Pharma

Epirus and Zalicus Announce Merger Agreement

Wed, 04/16/2014 - 13:13
Merger will create a publicly traded, global biosimilar enterprise focused on improving patient access to important medicines Epirus closes $36 million Series B financing round Management to Hold Conference Call at 8:30 a.m. EDT BOSTON--(Healthcar...
Biopharmaceuticals, Mergers & Acquisitions, Venture Capital
Epirus Biopharmaceuticals, Zalicus

Provista Diagnostics Secures $6MM Series B Financing

Wed, 04/16/2014 - 13:05
Scottsdale, Arizona, April 16, 2014 -- (Healthcare Sales & Marketing Network) -- Provista Diagnostics, Inc., a privately held molecular diagnostics company developing and commercializing diagnostic, prognostic and predictive tests for cancers affecting wom...
Diagnostics, Oncology, Venture Capital
Provista Diagnostics, dtectDx-Breast

OxThera AB Receives SEK 70 Million Financing to Continue its Key Clinical Programs

Wed, 04/16/2014 - 12:59
STOCKHOLM, April 16, 2014 -- (Healthcare Sales & Marketing Network) -- OxThera AB, a privately-held Stockholm-based biopharmaceutical company, today announced that a syndicate of new investors, led by Kurma Partners, including IdInvest Partners and Mayo C...
Biopharmaceuticals, Venture Capital
OxThera AB, Oxabact, Primary Hyperoxaluria

Wilson Therapeutics Secures $40 Million Private Financing To Advance Late Stage Development Program For Wilson's Disease

Wed, 04/16/2014 - 12:53
STOCKHOLM, April 16, 2014 -- (Healthcare Sales & Marketing Network) -- Wilson Therapeutics, a biopharmaceutical company, today announced that it has closed a $40 million Series B financing co-led by new investors, Abingworth LLP and MVM Life Science Partn...
Biopharmaceuticals, Venture Capital
Wilson Therapeutics, WTX101, Wilson's disease

Abiomed Acquires Exclusive License for Opsens' Optical Sensor Technology

Tue, 04/15/2014 - 15:18
Miniature Optical Pressure Sensors to be Integrated Into Impella Heart Pump Catheters DANVERS, Mass., April 15, 2014 -- (Healthcare Sales & Marketing Network) -- Abiomed, Inc. (ABMD), a leading provider of break-through heart support technologies, today...
Devices, Cardiology, Licensing
Abiomed, Opsens , fiber optic sensor, pressure sensor, Impella

Contact us     New York    l    Miami    l    Sao Paulo     l    Mexico DF    l    London    l    Hong Kong